Please login to the form below

Not currently logged in


This page shows the latest obinutuzumab news and features for those working in and with pharma, biotech and healthcare.

NICE backs Roche’s Gazyvaro after initial rejection

NICE backs Roche’s Gazyvaro after initial rejection

Last September the cost-effectiveness watchdog turned down Gazyvaro (obinutuzumab) for use with chemotherapy in previously-untreated patients with advanced follicular lymphoma (FL) at elevated risk of relapse, saying the dug

Latest news

More from news
Approximately 11 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...